Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 INDOCO REMEDIES   ACTAVIS
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-23
ACTAVIS
Dec-18
INDOCO REMEDIES/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs42316,037-   
Low Rs30810,758-   
Sales per share (Unadj.) Rs181.13,933.9-  
Earnings per share (Unadj.) Rs15.4-1,267.1-  
Cash flow per share (Unadj.) Rs23.1414.5-  
Dividends per share (Unadj.) Rs2.250-  
Avg Dividend yield %0.60-  
Book value per share (Unadj.) Rs111.516,225.6-  
Shares outstanding (eoy) m92.15332.60-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x2.03.4 59.3%   
Avg P/E ratio x23.7-10.6 -223.9%  
P/CF ratio (eoy) x15.832.3 49.0%  
Price / Book Value ratio x3.30.8 397.0%  
Dividend payout %14.60-   
Avg Mkt Cap Rs m33,6834,456,026 0.8%   
No. of employees `000NA16.9 0.0%   
Total wages/salary Rs m3,2260-   
Avg. sales/employee Rs Th077,421.7-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0-24,937.6-  
INCOME DATA
Net Sales Rs m16,6861,308,427 1.3%  
Other income Rs m2425,021 0.1%   
Total revenues Rs m16,7101,333,448 1.3%   
Gross profit Rs m2,86034,287 8.3%  
Depreciation Rs m706559,324 0.1%   
Interest Rs m25075,504 0.3%   
Profit before tax Rs m1,928-575,519 -0.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0146,780 0.0%   
Tax Rs m505-7,293 -6.9%   
Profit after tax Rs m1,423-421,445 -0.3%  
Gross profit margin %17.12.6 654.2%  
Effective tax rate %26.21.3 2,068.6%   
Net profit margin %8.5-32.2 -26.5%  
BALANCE SHEET DATA
Current assets Rs m8,082536,648 1.5%   
Current liabilities Rs m4,245474,737 0.9%   
Net working cap to sales %23.04.7 485.9%  
Current ratio x1.91.1 168.4%  
Inventory Days Days2520 128.1%  
Debtors Days Days76866 1,157.7%  
Net fixed assets Rs m9,055148,107 6.1%   
Share capital Rs m1840-   
"Free" reserves Rs m10,0920-   
Net worth Rs m10,2765,396,648 0.2%   
Long term debt Rs m1,4351,900,356 0.1%   
Total assets Rs m17,1378,436,189 0.2%  
Interest coverage x8.7-6.6 -131.4%   
Debt to equity ratio x0.10.4 39.7%  
Sales to assets ratio x1.00.2 627.8%   
Return on assets %9.8-4.1 -238.0%  
Return on equity %13.8-7.8 -177.3%  
Return on capital %18.6-4.8 -384.2%  
Exports to sales %47.50-   
Imports to sales %11.50-   
Net fx Rs m6,0020-   
CASH FLOW
From Operations Rs m1,788467,451 0.4%  
From Investments Rs m-2,082256,804 -0.8%  
From Financial Activity Rs m228-802,287 -0.0%  
Net Cashflow Rs m-65-77,642 0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 82.88 Rs / USD

Compare INDOCO REMEDIES With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare INDOCO REMEDIES With: ZIM LABORATORIES  ZENOTECH LABS  VEERHEALTH CARE  IOL CHEMICALS & PHARM.  AARTI PHARMALABS  



Today's Market

Sensex Today Trades Lower | Metal & PSB Stocks Shine | TCS, Apollo Tyre Drop 3% Sensex Today Trades Lower | Metal & PSB Stocks Shine | TCS, Apollo Tyre Drop 3%(10:30 am)

Asian shares slipped before a Bank of Japan policy decision where authorities are likely to bring an end to the world's last negative rates regime.